What Бронхорус treats: Main Uses and Benefits

This medication is generally used in situations involving certain distressing symptoms linked to respiratory conditions. Бронхорус is intended for conditions characterized by periods of heightened symptoms, including acute and chronic bronchopulmonary diseases where the chief difficulty is the presence of viscous, difficult-to-expel mucus. Common conditions where this is applied include acute bronchitis, Chronic Obstructive Pulmonary Disease (COPD), and chronic bronchitis, with additional supportive relief offered for local acute sore throat.

Applied in clinical settings where additional symptomatic support is needed, the medicine may assist with supporting functional stability by managing the challenge of persistent secretions. A key therapeutic benefit is the facilitation of expectoration, which contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress during symptomatic periods.

“This medicine is commonly used to help with the physical strain and discomfort caused by having to cough up thick, sticky phlegm.”

---

Quick Fact: Relief for Difficult Expectorating Cough

The core intent is to address ineffective productive cough, and it is used when symptoms are related to high viscosity and stickiness of phlegm, which requires assistance to be easier to move, and may assist with supporting the clearance of airways in adults and children.

Regulatory References

1. European Medicines Agency (EMA) Assessment Report

Who can and cannot use Бронхорус?

This section describes the officially documented population eligibility rules for Бронхорус (Ambroxol Hydrochloride), as stated in governmental regulatory documents.

---

Contraindicated Populations

Use of this medicine is absolutely contraindicated for patients with a known hypersensitivity to the active substance, Ambroxol, or to the related compound bromhexine. Use is also contraindicated during the first trimester of pregnancy.

---

Age and Physiological Restrictions

Population Group	Regulatory Eligibility Status
Children under 2 years	Generally not recommended or restricted without medical supervision.
Adults and Adolescents (ge 12 years)	Eligible for standard labeled use.
Breastfeeding Women	Not recommended, as the substance passes into breast milk.
Second and Third Trimesters of Pregnancy	Restricted use, permitted only after regulatory risk assessment.

---

Condition-Based Restrictions

Patients with severe renal impairment or severe hepatic impairment are eligible only for restricted use, often requiring consideration of modified administration. Caution is also required for patients with impaired bronchial motility or a history of gastric or duodenal ulcers, as noted in official prescribing information.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of the active substance, Ambroxol Hydrochloride, based on specific pharmacokinetic and pharmacodynamic patterns.

Pharmacodynamic and Contraindicated Combinations

Co-administration with cough suppressants (antitussives) is generally restricted in official labeling. This combination creates an antagonistic effect: while Бронхорус thins mucus, antitussives inhibit the cough reflex necessary to clear the thinned secretions. This pharmacodynamic conflict carries the documented risk of mucus retention in the airways.

Pharmacokinetic Alterations

Antibiotics: Co-administration with Ambroxol has a documented pharmacokinetic enhancement effect. Regulatory information states that this interaction leads to increased concentrations of certain antibiotics, including amoxicillin, cefuroxime, erythromycin, and doxycycline, in the bronchial secretions and lung tissue.

Population-Specific Clearance: The official prescribing information notes a specific pharmacokinetic caution for patients with severe hepatic or renal impairment. In these populations, the clearance of the medicine's metabolites may be reduced, potentially resulting in an increased systemic exposure of the active substance.

Food and Supplements: No clinically relevant interactions with food, alcohol, or herbal products are explicitly documented as restrictions in the official regulatory texts.

️ Modulation of Airway Secretions and Clearance

The active substance, Ambroxol Hydrochloride, acts as a secretagogue by stimulating specific cells in the lungs (Type II Pneumocytes) to increase the synthesis and release of pulmonary surfactant into the airways. Surfactant reduces the mucus's stickiness (adhesiveness), while the drug simultaneously facilitates the depolymerization of the thick structural fibers (mucopolysaccharides) within the secretions. This combined action reduces viscosity and restores the fluid-like state of the secretions, leading to the promotion of the Mucociliary Clearance Pathway—the body's natural mechanism for transporting secretions out of the respiratory tract.

Localized Sensory Nerve Blockade

The drug engages the peripheral nervous system by acting as a blocker of Neuronal Voltage-Gated Sodium Channels located on the sensory nerve endings in the upper airways. By inhibiting the rapid flux of sodium ions, the drug stabilizes the nerve fibers and interrupts the transmission of localized sensory input. This mechanism is primarily relevant for modulating localized sensory signaling patterns, leading to reduced action potential generation efficiency across the sensory nerve fibers originating from the respiratory lining.

️ Modulation of Local Inflammation

Beyond its mucoactive effects, the molecule also functions as a scavenger of Reactive Oxygen Species (ROS) and modulates the release of specific pro-inflammatory cytokines. This mechanistic domain reduces the concentration and activity of inflammatory mediators on the respiratory lining, thereby modulating the inflammatory cascade within the airway tissues.

How to Use Бронхорус

This section outlines the general administration principles and dosage patterns for Ambroxol Hydrochloride (the active ingredient in Бронхорус). Use of this medication is dictated by specific routes, dose ranges, and time constraints.

---

Administration Guidelines

Category	Instruction Statement
Route of Administration	Primarily Oral (tablets, syrups, capsules). Oromucosal routes are used for specific formulations (lozenges, sprays) for localized use, and Intravenous (IV) use is practiced in specialized clinical settings.
Dosing Schedule (Adults)	Treatment typically begins with an initial dose of 30 mg taken three times daily (total 90 mg/ day). This is followed by a maintenance dose of 30 mg twice daily (total 60 mg/ day).
Frequency	Standard forms are taken in divided doses two or three times daily, while sustained-release capsules (75 mg) are administered once daily.
Timing in Relation to Meals	Oral administration is generally advised to occur after a meal with sufficient fluid intake.

---

Procedural Structure and Constraints

The usage protocol establishes a two-phase pattern for oral administration, requiring the higher initial dosage to start the regimen before transitioning to the lower, regular maintenance dose. Liquid forms must be accurately measured using the provided dosing device. Sustained-release capsules must be swallowed whole to preserve their intended release characteristics. For self-care or acute use, the duration of use typically does not exceed four to five days without medical consultation. Dosage adjustments, involving lower doses or extended intervals, are required in cases of severe renal or hepatic impairment.

Evidence for Use in Chronic Bronchopulmonary Conditions

Research has explored Бронхорус in conditions characterized by fluctuating or episodic manifestations, such as chronic bronchitis and Chronic Obstructive Pulmonary Disease (COPD). The primary evidence in this area comes from numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that synthesize data from many individual studies. These studies were structured to examine outcomes related to physical discomfort and functional imbalance, including monitoring objective physical markers, such as measured changes in sputum viscosity and expectoration volume.

Research contributes to the broader evidence landscape; studies contribute to understanding symptom patterns in sputum properties and describe how symptoms evolved in the observed populations. The body of research monitored how symptoms evolved in the observed populations related to physical discomfort. However, evidence quality varies across studies, and some core data used in regulatory contexts were derived from trials conducted many years ago.

Evidence for Use in Acute Respiratory Infections

The evidence base for the use of Бронхорус in conditions associated with acute or disruptive episodes, such as acute bronchitis or pneumonia, also includes numerous Randomized Controlled Trials and historical clinical research. These studies were designed as research exploring short-term symptom changes. Research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Studies monitored how patients reported their experiences, focusing on outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states. The reported outcomes are typically based on short-term observation periods (e.g., 7 to 10 days).

What is Still Uncertain About the Research for Бронхорус

Key limitations are important to note when contextualizing the overall evidence landscape. Data for certain groups remain insufficient, and findings were mixed regarding the evidence for all use contexts in very young children, meaning certainty remains low in specific subgroups. Furthermore, there is limited information for long-term outcomes, as follow-up durations were limited in the core efficacy trials. Research provides context but not individual predictions about sustained outcomes beyond the study periods.

Common questions about Бронхорус (FAQ)

Q: What is Бронхорус and what is it used for?

A: Бронхорус is the trade name for a medication containing the active substance Ambroxol (hydrochloride). It is a type of mucolytic agent (sometimes called an expectorant).

It works by helping to thin and break down the mucus (phlegm) in the airways, making it easier to cough up. This can help clear the lungs and relieve chest congestion. It is primarily used to treat certain acute and chronic respiratory diseases where there is an abnormal production and transport of thick, sticky mucus, such as:

• Acute and chronic bronchitis
• Bronchial asthma
• Bronchiectasis

It is often used to relieve the symptoms associated with a productive cough (a cough that brings up phlegm).

---

Q: What is the difference between an expectorant, a mucolytic, and an antitussive?

A: These terms refer to different classes of medications used to treat cough and congestion, and they work in distinct ways:

• Mucolytic Agents (like Бронхорус/Ambroxol): These medications directly act on the chemical structure of mucus to break it down, making it less thick and sticky. This process is called mucolysis. The goal is to make the phlegm easier to remove.

• Expectorants: This term is sometimes used interchangeably with mucolytic, but it more broadly refers to agents that increase the volume or hydrate the secretions, which helps thin the mucus and promotes its removal (expectoration).

• Antitussives (Cough Suppressants): These medications are used to suppress the cough reflex, stopping or reducing the frequency of coughing. They are typically used for a dry, non-productive cough (a cough that does not bring up phlegm).

Key Difference: Mucolytics/Expectorants aim to facilitate a productive cough, while Antitussives aim to stop the cough reflex.

---

Q: What are the potential common side effects of Бронхорус?

A: Like all medicines, Бронхорус (Ambroxol) can cause side effects, although not everybody gets them. The most common side effects are often mild and affect the gastrointestinal system or involve allergic reactions.

Common Side Effects (may affect up to 1 in 10 people):

• Taste disturbance (dysgeusia)
• Nausea
• Oral numbness (oral hypoesthesia)
• Pharyngeal numbness (pharyngeal hypoesthesia)

Uncommon Side Effects (may affect up to 1 in 100 people):

• Vomiting
• Diarrhea
• Dyspepsia (indigestion)
• Abdominal pain
• Dry mouth
• Fever

Rare Side Effects (may affect up to 1 in 1,000 people):

• Hypersensitivity reactions (such as skin rash)

Very Rare Side Effects:

• Severe cutaneous adverse reactions (SCARs), including erythema multiforme, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP).

If you experience any signs of a severe allergic or skin reaction, you should stop taking the medication and seek immediate medical attention.

---

Q: Can Бронхорус be taken with other cough or cold medications?

A: Combining Бронхорус (Ambroxol) with certain other cough and cold medications can be problematic and is generally not recommended.

• Do not combine with Antitussives: It is generally advised not to take Ambroxol with cough suppressants (antitussives). Ambroxol promotes the production and thinning of mucus to facilitate coughing, while antitussives suppress the cough reflex. Taking them together could lead to an accumulation of mucus in the lungs, as the mucolytic action is working but the mechanism for clearing the mucus (the cough) is being blocked.

• Antibiotics: Studies have shown that Ambroxol may increase the concentration of certain antibiotics (e.g., amoxicillin, cefuroxime) in the bronchial secretions. This interaction is generally considered beneficial in the context of treating respiratory infections.

• Other Medications: Always consult with a healthcare provider or pharmacist before combining any cough, cold, or flu medications, as they may contain multiple ingredients that could interact with Ambroxol or with each other.

---

Q: Should I take Бронхорус before or after meals?

A: Бронхорус (Ambroxol) can generally be taken with or without food. Taking the medication with food may help minimize any potential gastrointestinal discomfort, such as nausea or stomach upset, which are among the potential side effects of the medication.

It is important to follow the specific instructions provided on the packaging insert or by your healthcare provider, particularly regarding the frequency and timing of the doses.

The official regulatory requirements for storing and disposing of Бронхорус are designed to maintain its stability and ensure safety.

Storage Requirements

Dosage Form	Required Storage Condition
Tablets	Store in a dry place protected from light, at a temperature not higher than 25°C.
Syrup	Store protected from light, within the temperature range of 15 C to 25 C.

All forms of the medicine must be stored in a place inaccessible to children.

Stability and Disposal

The labeled shelf life for the tablets is 5 years, and for the syrup, it is 3 years. The product must not be used after its expiration date. Official instructions require that unused or expired medicine be disposed of according to local regulations for pharmaceutical waste, as no specific household disposal method is documented in the core regulatory texts.